Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals

Core Insights - J.P. Morgan analyst Lisa C. Gill has updated estimates for Agilon Health, Inc. following the fourth-quarter results, indicating a Neutral rating for the stock [1] Financial Performance - Agilon Health reported a fourth-quarter 2024 adjusted EPS of $(0.26), which missed the consensus estimate of $(0.23) [1] - The company's sales for the quarter were $1.52 billion, aligning with expectations [1] Future Outlook - For FY25, the revenue estimate has been revised to $5.926 billion, slightly below the consensus of $5.928 billion, down from an earlier estimate of $6.453 billion [3] - The adjusted EBITDA loss estimate for FY25 remains unchanged at $77 million, compared to a consensus loss of $78 million [3] - For FY26, the revenue estimate has been updated to $6.594 billion, below the consensus mean of $6.665 billion, down from a prior estimate of $7.319 billion [3] - The adjusted EBITDA loss estimate for FY26 has changed to $23 million, compared to a consensus loss of $22 million, revised from a previous loss estimate of $10 million [3] Strategic Positioning - The company is expected to navigate a year of transition in 2025, addressing specific challenges while positioning itself to achieve targets for 2026/2027 [2] Investment Opportunities - Investors can gain exposure to Agilon Health through Fidelity Disruptive Medicine ETF FMED and SPDR S&P Health Care Services ETF XHS [4] - As of the last check, AGL shares are down 0.48% at $4.18 [4]